louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06063707: The Effect of rTEM in the Prognosis and Severity of Sepsis Induced ARDS
Official title: The Effect of rTEM in the Prognosis and Severity of Sepsis Induced ARDS
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Sepsis
Lead sponsor: Southeast University, China
Sponsor class: OTHER
First posted: 2023-10-02
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study enrolled sepsis patients

Brief summary: To observe the changes of plasma rTEM levels in patients with sepsis, sepsis induced ARDS, and to explore its clinical significance.

Detailed description: 90 patients will be included in this study. Blood samples from these patients in the first day, the third day, were maintained and tested to detect the change of rTEM level. Severity of illness and survival status of every patient were recorded within 28 days. The objective is to observe the changes of plasma rTEM levels in patients with sepsis, sepsis induced ARDS, and to explore its clinical significance.

Eligibility criteria: Inclusion Criteria:

Diagnosed as Sepsis 3.0 Patients signing informed consent

Exclusion Criteria:

Pregnant women Patients with tumor、hepatitis、liver cirrhosis、acute myocardial infarction、chronic renal tubular nephritis、interstitial pneumonia、acute pancreatitis、systemic lupus erythenatosus、ulcerative colitis、crohn's disease、HELLP syndrome

Primary outcomes:
measure: Mortality
timeFrame: 28 day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Southeast University
name: Jingyuan Xu, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03115307: Luteal Phase Support in Insemination Cycles
Official title: A Protocol for a Randomized, Controlled Study to Compare the Use of Gonodotropin-releasing Hormone Agonist Triptoreline (Gonapeptyl®) for Luteal Phase Support Versus Natural Luteal Phase in the Insemination Cycles
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Infertility, Female
Keywords: Insemination
Luteal phase support
Gonadotropin-releasing hormone agonist
Triptorelin
Lead sponsor: Tampere University Hospital
Sponsor class: OTHER
First posted: 2017-04-14
Enrollment: 167
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 43
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a prospective randomized trial with 242 IUI cycles. Patients are randomized in two groups including 121 cycles in each group. A total of 255 cycles in 167 patients are finally recruited. In the first group, the patients will be treated with triptorelin (Gonapeptyl®) in their luteal phase. As for the other group, the patients will undergo the luteal phase without any supportive medication. This study is going to clarify the role of the gonadotropin agonist (triptorelin acetate, Gonapeptyl®) as a luteal phase supporter. The benefit of the treatment is measured by the numbers in the live birth and clinical pregnancy rates.


Eligibility criteria: Inclusion Criteria:

* - Patients with ovarian stimulation cycles preparing to insemination
* Patients with medical ovarian stimulation protocols including GnRH agonist, aromatase inhibitors and different combinations of GnRH agonists and aromatase inhibitors are included
* Patient's willingness to participate in the study

Exclusion Criteria:

* - Failure in the ovarian stimulation cycle
* Failures in executing the insemination
* Failures in giving the sperm sample
* Major troubles in sperm parameters leading to an inadequate sample to accomplish intrauterine insemination
* Patients with primarily planned progesterone luteal support

Primary outcomes:
measure: Live birth rate
timeFrame: At possible delivery (about 40 weeks)
Secondary outcomes:
measure: Ongoing pregnancy rate
timeFrame: After two weeks
measure: Miscarriage rate
timeFrame: During subsequent about 40 weeks of pregnancy
Other outcomes:
Locations:
city: Tampere
country: Finland
facility: Tampere University Hospital
Study officials:
affiliation: Tampere University Hospital
name: Helena Tinkanen
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03985007: CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Official title: Chidamide, Decitabine Combined With Priming IAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Acute Myeloid Leukemia, Relapsed, Adult
Keywords: chidamide
decitabine
priming regimen
Lead sponsor: The First Affiliated Hospital of Soochow University
Sponsor class: OTHER
Collaborators: name: Jining Medical University
First posted: 2019-06-13
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is to investigate the therapeutic efficacy and side effect of chidamide, decitabine combined with priming IAG regimen for relapsed or refractroy acute myeloid leukemia


Eligibility criteria: Inclusion Criteria:

* Relapsed or refractory acute myeloid leukemia patients without severe complications such as active infections and bleedings; ECOG score less than 3.

Exclusion Criteria:

* Inablity to tolerate inducton chemotherapy; life expectancy less than 1 month

Primary outcomes:
measure: Remission Rate
timeFrame: 1 month
measure: Overall survial
timeFrame: 1 year
Secondary outcomes:
measure: Adverse events in hematological system
timeFrame: 1 month
measure: Adverse events in other organs or systems
timeFrame: 1 month
Other outcomes:
Locations:
city: Suzhou
country: China
facility: The First Affliated Hospital of Soochow University
state: Jiangsu
Study officials:
References:
citation: Yin J, Wan CL, Zhang L, Zhang H, Bai L, Zhou HX, Xu MZ, Chen LY, Qian CS, Qiu HY, Chen SN, Tang XW, Wu DP, Zhang YM, Sun AN, Xue SL. A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2021 Sep 3;11:726926. doi: 10.3389/fonc.2021.726926. eCollection 2021.
Clinical trial NCT00218907: An Educational HIV Pre-Test Counseling Video Program for Off Hours Testing in the ED: A Randomized Control Trial
Official title: An Educational HIV Pre-Test Counseling Video Program for Off Hours Testing in the ED: A Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: HIV Counseling and Testing
HIV Infections
Keywords: HIV prevention
HIV counseling
HIV testing
Emergency Medicine
HIV Seronegativity
Lead sponsor: North Bronx Healthcare Network
Sponsor class: OTHER
First posted: 2005-09-22
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: ECT

Brief summary: This study compared the educational effectiveness of a ten-minute pre-test counseling video with the usual practice of a session with an HIV counselor.

Detailed description: HIV is increasingly affecting urban populations, making the inner city ED a prime venue for C\&T because of their unique opportunity to identify HIV positive patients. These underserved communities often use the ED for their regular health care specifically because it provides services outside of the usual weekday working hours. However, there are significant barriers to HIV C\&T in the ED, such as the lack of resources to provide prevention oriented messages, cost issues, and the feasibility of providing the required manpower for testing. The objective of this study is to determine whether an educational video, with the required pre-test counseling elements, conveys the necessary information for inner city ED patients to consent to a standard Elisa HIV test.

In order to address the HIV testing needs of the patient population presenting to the ED, innovative methods must be developed to provide HIV C\&T, while simultaneously removing the barriers to testing. Video technology may provide an opportunity to make HIV counseling feasible when counselors are not available.

Eligibility criteria: Inclusion Criteria:

* All patients awaiting UC treatment were approached for the study.
* Patients 18 years of age and older were included
* Patients who spoke English and Spanish were included.

Exclusion Criteria:

* Clinically unstable,
* Diagnosed with HIV
* Unable to understand the consent process because such patients require unique arrangements for consenting processes.

Primary outcomes:
measure: Comparison of mean knowledge score in both groups.
Secondary outcomes:
Other outcomes:
Locations:
city: Bronx
country: United States
facility: Jacobi Medical Center
state: New York
Study officials:
affiliation: Jacobi Medical Center, Albert Einstein College of Medicine
name: Yvette Calderon, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02111707: Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)
Official title: Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Acute Pancreatitis
Lead sponsor: University of Alberta
Sponsor class: OTHER
First posted: 2014-04-11
Enrollment: 534
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To determine if the timing of administration of indomethacin affects the primary outcome of post-ERCP pancreatitis (PEP). Patients undergoing ERCP will be randomly assigned to receive pre or post-procedure rectal indomethacin to prevent the occurrence of PEP.


Eligibility criteria: Inclusion Criteria:

* All patients referred for ERCP at the University of Alberta
* Age greater than 18 years
* Ability to provide written informed consent

Exclusion Criteria:

* Acute pancreatitis
* Active peptic ulcer disease
* Rectal disease
* Aspirin-induced asthma
* Nonsteroidal anti-inflammatory drug (NSAIDs) induced hypersensitivity
* Pregnancy
* Breast feeding
* Creatinine clearance \< 30 ml/min

Primary outcomes:
measure: Rate of Post-ERCP pancreatitis
timeFrame: 30 days
Secondary outcomes:
measure: Severity of Post-ERCP pancreatitis
timeFrame: 30 days
Other outcomes:
Locations:
city: Edmonton
country: Canada
facility: University of Alberta
state: Alberta
Study officials:
References:
citation: Sotoudehmanesh R, Khatibian M, Kolahdoozan S, Ainechi S, Malboosbaf R, Nouraie M. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol. 2007 May;102(5):978-83. doi: 10.1111/j.1572-0241.2007.01165.x. Epub 2007 Mar 13.
citation: Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, Hayward RA, Romagnuolo J, Elta GH, Sherman S, Waljee AK, Repaka A, Atkinson MR, Cote GA, Kwon RS, McHenry L, Piraka CR, Wamsteker EJ, Watkins JL, Korsnes SJ, Schmidt SE, Turner SM, Nicholson S, Fogel EL; U.S. Cooperative for Outcomes Research in Endoscopy (USCORE). A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012 Apr 12;366(15):1414-22. doi: 10.1056/NEJMoa1111103.
citation: Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology. 2003 Jun;124(7):1786-91. doi: 10.1016/s0016-5085(03)00384-6.
citation: Montano Loza A, Rodriguez Lomeli X, Garcia Correa JE, Davalos Cobian C, Cervantes Guevara G, Medrano Munoz F, Fuentes Orozco C, Gonzalez Ojeda A. [Effect of the administration of rectal indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes]. Rev Esp Enferm Dig. 2007 Jun;99(6):330-6. doi: 10.4321/s1130-01082007000600005. Spanish.
Clinical trial NCT00127907: Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest
Official title: Comparison of Epinephrine Associated With Vasopressin vs Epinephrine Alone in the Treatment of Out-of-Hospital Cardiac Arrests
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cardiac Arrest
Keywords: Out-of-hospital cardiac arrest - Vasopressin - Epinephrine
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2005-08-09
Enrollment: 2416
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Recent studies have suggested that arginine-vasopressin could be more effective in the treatment of cardiac arrests. The last published study did not outline obvious improvements in the prognosis of all cardiac arrests but pointed out a possible increased survival rate when arginine-vasopressin is associated with epinephrine. The aim of this study is to compare the efficacy of two successive injections of epinephrine (1 mg) with two successive injections of epinephrine associated with arginine-vasopressin (40 UI) in out-of-hospital cardiac arrests occurring in adult patients. The primary endpoint is the survival rate at hospital admission. The inclusion period lasts 18 months and 2416 patients are planned to be enrolled.


Eligibility criteria: Inclusion Criteria:

* Out-of-hospital medical cardiac arrest in adult patients.

Exclusion Criteria:

* Traumatic cardiac arrest
* Pregnancy
* Patients younger than 18 years old or older than 85 years old

Primary outcomes:
measure: Survival at hospital admission
Secondary outcomes:
measure: ROSC (Return of spontaneous circulation) Survival at : H24, Day 28, hospital discharge and one year Neurological status at H24 and hospital discharge.
Other outcomes:
Locations:
city: Pierre Bénite
country: France
facility: Centre Hospitalier Lyon Sud
Study officials:
affiliation: Hospices Civils de Lyon
name: Pierre-Yves GUEUGNIAUD, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gueugniaud PY, David JS, Chanzy E, Hubert H, Dubien PY, Mauriaucourt P, Braganca C, Billeres X, Clotteau-Lambert MP, Fuster P, Thiercelin D, Debaty G, Ricard-Hibon A, Roux P, Espesson C, Querellou E, Ducros L, Ecollan P, Halbout L, Savary D, Guillaumee F, Maupoint R, Capelle P, Bracq C, Dreyfus P, Nouguier P, Gache A, Meurisse C, Boulanger B, Lae C, Metzger J, Raphael V, Beruben A, Wenzel V, Guinhouya C, Vilhelm C, Marret E. Vasopressin and epinephrine vs. epinephrine alone in cardiopulmonary resuscitation. N Engl J Med. 2008 Jul 3;359(1):21-30. doi: 10.1056/NEJMoa0706873.
Clinical trial NCT01746407: Procurement of Human Specimens for the Evaluation of Early Markers of Sepsis
Official title: Observational Study to Procure Human Specimens for Use in the Diagnosis and Management of Sepsis and Other Related Conditions
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infection
Keywords: Emergency Department
Infection
Sepsis
Lead sponsor: Abbott Diagnostics Division
Sponsor class: INDUSTRY
First posted: 2012-12-11
Enrollment: 872
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Presentation to an emergency department

Brief summary: Procure blood specimens from individuals presenting to the emergency department (ED) with signs and /or symptoms of systemic infection or sepsis. The samples will be used for research and development activities related to sepsis, infections, etc.


Eligibility criteria: Inclusion Criteria:

* 18 yrs of age or older
* For women of child bearing years: not known to be pregnant
* Blood culture ordered as part of the ED, ICU (or equivalent) or hospital floor stay.

Exclusion Criteria:

* Previously enrolled in this study
* Vulnerable individual
* Unable to speak and/or understand English

Primary outcomes:
measure: Progression of infection to severe sepsis
timeFrame: 72 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Emory University Hospital
state: Georgia
city: Atlanta
country: United States
facility: Grady Memorial Hospital
state: Georgia
Study officials:
affiliation: Emory University
name: Greg S Martin, MD, M.Sc.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02504307: OCT Evaluation 3 Months After Sirolimus Eluting Stent Implantation
Official title: Randomized Evaluation of Vascular Healing After Implantation of Sirolimus Eluting Stent Inspiron™ Versus Its Own Bare Metal Version- An OCT Evaluation After 3 Months Follow-up
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Coronary Artery Disease
Lead sponsor: Scitech Produtos Medicos Ltda
Sponsor class: INDUSTRY
First posted: 2015-07-21
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Prospective, single center, randomized and non-inferiority study, to include up to 60 patients with de novo coronary artery disease. Patients will be followed at 30 days, 3, 6 and 12 months. At 3 months all patients will be submitted to angiographic and OCT evaluation.


Eligibility criteria: Inclusion Criteria:

* one or two de novo lesions (\> 50% visual estimation)
* lesion diameter between 2.5 and 3.5 mm
* lesion length up to 33 mm.

Exclusion Criteria:

* MI within the last 72 hours
* restenotic lesion.

Primary outcomes:
measure: Safety
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Rio de Janeiro
country: Brazil
facility: Instituto Nacional de Cardiologia
state: RJ
Study officials:
affiliation: Insituto Nacional de Cardiologia
name: Sergio Leandro, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01654107: Persistence-Targeted Smoking Cessation
Official title: Persistence-Targeted Smoking Cessation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Tobacco Use Disorder
Keywords: tobacco
smoking cessation
nicotine dependence
Lead sponsor: Rutgers, The State University of New Jersey
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2012-07-31
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators propose to develop a theory-based smoking cessation intervention (called Persistence-targeted smoking cessation; PTSC). PTSC includes 8 weekly individual counseling sessions and use of nicotine lozenge for 12 weeks. The investigators will test the feasibility and preliminary efficacy of the intervention (i.e., cigarettes per day and prolonged abstinence).

Detailed description: In this Stage I Behavioral \& Integrative Treatment Development (R34) project, we propose to develop a theory-based smoking cessation intervention (called Persistence-targeted smoking cessation; PTSC). PTSC includes 8 weekly individual counseling sessions and use of nicotine lozenge for 12 weeks. We will test the feasibility and preliminary efficacy of the intervention (i.e., cigarettes per day and prolonged abstinence). We hope to develop a feasible psychosocial treatment for use in a later randomized controlled trial.

Eligibility criteria: Inclusion Criteria:

* Must be between 18 - 64 years old
* Must smoke at least 10 cigarettes per day for past 6-months
* Expired breath carbon monoxide (CO) \> 7
* Must have a working cellular phone

Exclusion Criteria:

* Must not be currently receiving tobacco dependence treatment counseling
* Must not currently be taking varenicline, bupropion, or any nicotine preparations (gum, lozenge, patch, spray, inhaler)
* Must have no contraindications to using nicotine lozenge

Primary outcomes:
measure: 7-day Point Prevalence Abstinence
timeFrame: 3-months
Secondary outcomes:
Other outcomes:
Locations:
city: New Brunswick
country: United States
facility: Rutgers Robert Wood Johnson Medical School
state: New Jersey
Study officials:
affiliation: Rutgers, The State University of New Jersey
name: Marc L Steinberg, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04360707: Solid Organ Transplant Recipients With SARS-CoV-2 French Registry
Official title: Clinical Presentation and Incidence of SARS-CoV-2 Infection in Different Cohorts of Solid Organ Transplant Patients and Follow-up in France
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: SARS-CoV-2
Keywords: SARS-CoV-2
Covid-19
Solid Organ transplantation
Incidence
Prognosis
Cellular response
Humoral Response
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2020-04-24
Enrollment: 300
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All Solid Organ Transplant recipients with a functioning graft and a high suspicion or a confirmed SARS-CoV-2 infection

Brief summary: Patients with comorbid condition are known to be at high risk of severe forms of Covid-19. It is highly probable that immunocompromised patients like solid organ transplant (SOT) recipients are also at risk of severe forms of Covid-19. For this purpose, The investigators conducted a nationwide multicentric and multiorgan Registry to collect data about all French SOT recipients who develop a SARS-CoV-2 infection. The aim is to describe the clinical, biological and virological characteristics of these patients and to give information about evolution and prognosis of these particular population


Eligibility criteria: Inclusion Criteria:

* All Solid Organ Transplant recipients with a functioning graft and a high suspicion or a confirmed SARS-CoV-2 infection
* Adult and pediatric

Exclusion Criteria:

- There are no exclusion criteria, except for the patient's explicit refusal to participate

Primary outcomes:
measure: Clinical Presentation and Incidence of Covid-19 Infection in Different Cohorts of Solid Organ Transplant Patients
timeFrame: From 1st March 2020 to 1st March 2021
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de Néphrologie et Transplantation
Study officials:
affiliation: Service de Néphrologie et Transplantation
name: Sophie CAILLARD, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Gerard AO, Barbosa S, Anglicheau D, Couzi L, Hazzan M, Thaunat O, Blancho G, Caillard S, Sicard A; French SOT COVID Registry. Association Between Maintenance Immunosuppressive Regimens and COVID-19 Mortality in Kidney Transplant Recipients. Transplantation. 2022 Oct 1;106(10):2063-2067. doi: 10.1097/TP.0000000000004254. Epub 2022 Jul 27.